Author Archives: Marta Figueiredo

Variant’s Experimental Therapy HPβCD May Halt Kidney Damage in Alport Syndrome, Mouse Study Shows

Variant Pharmaceuticals’ investigational therapy hydroxypropyl beta cyclodextrin (HPβCD) may prevent progressive kidney damage and fibrosis (scarring) in people with Alport syndrome, according to preclinical results in a mouse model of the disease. These findings also support a hypothesis stating that lipid (fat) accumulation in the kidneys contributes to…

Create your own user feedback survey